Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management
Source: OncLive, February 2025
Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.
Doublet immunotherapy remains the preferred first-line option for patients with melanoma regardless of BRAF mutation status; however, according to long-term findings from several key clinical and sequencing trials, administering targeted therapy alone or before and after immunotherapy may be appropriate for select patients with high disease burden, visceral crisis, or symptomatic brain metastases, according to Teresa Petrella, MD, MHSc, FRCPC.
In an interview with OncLive® regarding her presentation at the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies, Petrella discusses long-term survival and sequencing data that inform frontline treatment selection between immunotherapy and targeted therapies for metastatic melanoma. This included findings from the phase 2 SECOMBIT (NCT02631447) and phase 3 DREAMseq (NCT02224781) trials, as well as long-term data from the phase 3 KEYNOTE-006 (NCT01866319), CheckMate 067 (NCT01844505) and COLUMBUS (NCT01909453) trials.